Homology Medicines is a genetic medicines company. Co.'s proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors to deliver single administration genetic medicines in vivo either through its gene therapy, Co.'s nuclease-free gene editing modality, or Co.'s gene therapy to express antibodies platform. Co.'s clinical programs include: HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria; as well as HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with PKU. The FIXX average annual return since 2018 is shown above.
The Average Annual Return on the FIXX average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether FIXX average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FIXX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|